INTRODUCTION
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell lymphotropic virus type I. 1 Patients with aggressive ATLL, such as acute type and lymphoma type, still have a dismal outcome, even with intensive chemotherapy. [2] [3] [4] [5] [6] Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is an important treatment option for patients with aggressive ATLL, as previously reported.
rate in patients who received Mog compared with those who received conventional chemotherapy without Mog, although no statistical significance was found in overall survival (OS). 10 Regulatory T cells (Tregs) play an important role in the maintenance of immune tolerance after allo-HSCT.
11, 12 Because Tregs highly express CCR4, a target of Mog, they are significantly depleted in vivo for several months after the administration of Mog (half-life, 16 to 18 days). 8 Therefore, major concerns exist about the use of Mog before allo-HSCT because pretransplantation administration of Mog could theoretically exacerbate acute graftversus-host disease (GVHD) in patients with ATLL; depletion of Tregs abrogates the maintenance of immune tolerance after allo-HSCT, as suggested in animal models. However, no direct evidence has demonstrated Treg depletion in humans. Although several groups previously reported the adverse effects of pretransplantation Mog, the number of patients who received Mog before allo-HSCT was small. 13, 14 To clarify this issue, we used a database constructed by a nationwide survey of aggressive ATLL in Japan to analyze retrospectively the outcomes of patients with ATLL who underwent allo-HSCT.
PATIENTS AND METHODS

Data Source
We conducted a nationwide survey of patients with aggressive ATLL to construct a new large database. This study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan. First, we invited 232 hospitals with a department of hematology to complete a survey, of which 99 participating hospitals returned the questionnaire to the data center. From the nationwide survey, we included patients who fulfilled the following criteria: 70 years old or younger, aggressive ATLL (acute-and lymphoma-type ATLL), diagnosis between 2000 and 2013, and receipt of intensive chemotherapy from multiple chemotherapeutic drugs as first-line therapy. In total, data from 2,703 patients were registered. We analyzed the clinical outcome of patients who received allo-HSCT. Nine hundred ninety-six patients were included in this analysis. The cohort overlapped with a previous one from our institute. 14 Acute GVHD was diagnosed and graded according to previously described criteria. 15 Responses to corticosteroid were defined as refractory if the grade was unchanged or worsened after first-line corticosteroid therapy or if second-line systemic treatment of acute GVHD was added as previously reported. 16 Grading and response were determined by the physicians.
Statistical Analysis
Differences between patients who received Mog before allo-HSCT and those who did not were compared by x 2 test or Fisher exact test for categorical variables and t test or Mann-Whitney U test for continuous variables. The OS rates were computed from the survival curves estimated by the Kaplan-Meier method. OS was defined as the time from allo-HSCT until death, with censoring on the last known alive date. A Cox proportional hazards regression model was used to analyze OS. The cumulative incidence of nonrelapse mortality (NRM) was evaluated by the model of Fine and Gray 17 for univariable and multivariable analyses. In the competing risk model for NRM, relapse was defined as a competing risk. NRM was defined as the time from allo-HSCT until death without relapse, and relapse was defined as the time from allo-HSCT until relapse, with censoring on the last known alive date. A two-sided P , .05 was considered statistically significant.
In terms of the analyses for acute GVHD, because of the lack of data about onset of GVHD in this survey, multiple logistic regression analysis was used to assess which variables were significantly associated with the development of grade 2 to 4 or grade 3 to 4 acute GVHD (Appendix Table  A1 , online only). The variables that were evaluated in these analyses were as follows: sex mismatch (female to male v others), patient age at the time of diagnosis ( 1, 18 In terms of grouping by stem cell source, we used four groups of patients as previously reported. 7, 19 The median interval from the last administration of Mog to allo-HSCTwas 45 days. The cutoff value for the interval from the last administration of Mog to allo-HSCT was also examined by using receiver operating characteristic analysis. The value that generated the highest sensitivity and specificity was 41 days; therefore, we chose 50 days as a threshold in this study. All statistical analyses were performed with EZR (Saitama Medical Centre, Jichi Medical University, Shimotsuke, Japan; www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html), a graphical user interface for R version 3.0.2 (The R Foundation for Statistical Computing, Vienna, Austria). 20 More precisely, EZR is a modified version of R Commander version 2.0.3 that incorporates widely used packages, including survival and cmprsk.
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1 . The median age was 55 years (range, 20 to 69 years). Patients who received Mog before allo-HSCT (Mog group) were significantly older than those who did not receive Mog (no-Mog group; median age, 61 v 55 years, respectively; P , .01). Compared with the no-Mog group, the Mog group included more patients with acute-type ATLL (84.1% v 70.1%; P , .01) and patients who received a reduced-intensity conditioning regimen before allo-HSCT (73.8% v 61.5%; P = .03). Almost all patients in the Mog group were diagnosed between 2008 and 2013. The median interval from the last administration of Mog to allo-HSCTwas 45 days (range, 9 to 1,077 days). The total number of administered doses of Mog was five or more in 37 patients, fewer than five in 40 patients, and unknown in five patients.
Acute GVHD and NRM
In evaluable patients with data on acute GVHD (954 of 996), grade 2 to 4 acute GVHD occurred in 381 of 873 (43.6%) in the noMog group and in 47 of 81 (58.0%) in the Mog group (relative risk [RR], 1.33; 95% CI, 1.09 to 1.62; P = .01). Grade 3 to 4 acute GVHD occurred in 150 (17.2%) patients in the no-Mog group and in 25 (30.9%) in the Mog group (RR, 1.80; 95% CI, 1.26 to 2.57; P , .01). In multivariable analyses, pretransplantation Mog was associated with the incidence of grade 2 to 4 and grade 3 to 4 acute GVHD (Appendix Table 1 , online only). Systemic corticosteroids were used for acute GVHD in 341 of 570 (59.8%) patients in the no-Mog group and in 47 of 64 (73.4%) in the Mog group (RR, 1.23; 95% CI, 1.04 to 1.44; P = .03). In these patients, refractoriness to systemic corticosteroids for acute GVHD was observed in 80 of 341 (23.5%) patients in the no-Mog group and 23 of 47 (48.9%) in the Mog group (RR, 2.09; 95% CI, 1.47 to 2.96; P , .01).
One-year cumulative incidence of NRM was 25.1% (95% CI, 22.3% to 27.9%) in the no-MOG group and 43.7% (95% CI, 32.6% to 54.3%) in the Mog group (P , .01; Fig 1A) . In multivariable analysis, pretransplantation MOG was a significant risk factor for NRM (hazard ratio [HR], 1.93; 95% CI, 1.29 to 2.88; P , .01; Table 2 ).
Relapse/Progression and OS
One-year cumulative incidence of relapse/progression was 35.2% (95% CI, 32.1% to 38.3%) in the no-Mog group and 32.3% (95% CI, 22.1% to 43.0%) in the Mog group (P = .66; Fig 1B) . In multivariable analysis, pretransplantation MOG was not a significant risk factor, and pretransplantation disease status was a strong predictor for relapse/progression (v CR: PR HR, 1.35 [95% CI, 1.04 to 1.76; P = .02]; SD HR, 1.50 [95% CI, 1.00 to 2.25; P = .05]; PD HR, 2.57 [95% CI, 1.87 to 3.51; P , .01]; Table 2 ).
The estimated probabilities of 1-year OS were 49.4% (95% CI, 46.1% to 52.6%) in the no-Mog group and 32.3% (95% CI, 22.3% to 42.6%) in the Mog group (P , .01, Fig 1C) . In multivariable analysis, pretransplantation MOG was a significant risk factor for overall mortality (HR, 1.67; 95% CI, 1.23 to 2.26; P , .01; Table 2 ). As another important factor, pretransplantation disease status was a significant prognostic factor for overall mortality (v CR: PR HR, 1.36 [95% CI, 1.10 to 1.68; P = .01]; SD HR, 1.85 [95% CI, 1.35 to 2.53; P , .01]; PD HR, 3.12 [95% CI, 2.46 to 3.94; P , .01]; Fig 1D; Table 2 ).
Impact of Interval Between the Last Mog Administration and Allo-HSCT
The median interval between the last Mog administration and allo-HSCT was 45 days (range, 9 to 1,077 days). We divided the Mog group into two groups according to the interval between the last Mog administration and allo-HSCT as follows: interval between the last Mog administration and allo-SCT $ 50 days (n = 38; $ 50 days Mog group) and interval between the last Mog administration and allo-HSCT , 50 days (n = 42; , 50 days Mog Abbreviations: ATLL, adult T-cell leukemia/lymphoma; BM, bone marrow; CR, complete remission; GVHD, graft-versus-host disease; HSCT, hematopoietic stem-cell transplantation; Mog, mogamulizumab; PBSC, peripheral blood stem cells; PD, progressive disease; PR, partial remission; SD, stable disease; sIL2R, soluble interleukin 2 receptor. *Data on acute GVHD were available for 873 patients in the no-Mog group and 81 patients in the Mog group. †Percentage was calculated for patients in whom acute GVHD developed (570 patients in the no-Mog group and 64 patients in the Mog group). ‡Percentage was calculated for patients who received systemic corticosteroids for acute GVHD (341 patients in the no-Mog group and 47 patients in the Mog group).
group). One-year cumulative incidences of NRM were 34.4% (95% CI, 19.6% to 49.7%) in the $ 50 days MOG group and 55.1% (95% CI, 38.1% to 69.2%) in the , 50 days Mog group (P , .01; Fig 2A) . In multivariable analysis, pretransplantation Mog with intervals of , 50 days to allo-HSCT was associated with an increased risk of NRM (v no pretransplantation Mog: interval between Mog and allo-SCT $ 50 days HR, 1.58 [95% CI, 0.86 to 2.91; P = .14]; interval between Mog and allo-HSCT , 50 days HR, 2.26 [95% CI, 1.40 to 3.66; P , .01]; Appendix Table A2 , online only). The estimated probabilities of 1-year OS was 44.1% (95% CI, 28.0% to 59.1%) in the $ 50 days Mog group and 20.2% (95% CI, 9.5% to 33.8%) in the , 50 days Mog group (P , .01; Fig 2B) . In multivariable analysis, pretransplantation Mog with intervals of , 50 days to allo-SCT was associated with an inferior OS (v no pretransplantation Mog: interval between Mog and allo-HSCT $ 50 days HR, 1.30 [95% CI, 0.84 to 2.01; P = .25]; interval between Mog and allo-HSCT , 50 days HR, 2.02 [95% CI, 1.37 to 2.98; P , .01]; Appendix Table 2 ).
DISCUSSION
The results from a large database study show that pretransplantation Mog is associated with an increased risk of severe/ 
The cumulative incidence of (A) nonrelapse mortality, (B) relapse, and (C) estimated probability of overall survival, stratified by the use of pretransplantation mogamulizumab. (D) The estimated probability of overall survival was grouped according to pretransplantation disease status. HSCT, hematopoietic stem-cell transplantation; Mog, mogamulizumab.
www.jco.org refractory acute GVHD and NRM, which leads to an inferior OS after allo-HSCT. We assume that pretransplantation Mog persists in the body for several months and continuously depletes Tregs before and after allo-HSCT. Persistent Mog depletes Tregs and disrupts immune tolerance after allo-HSCT, which leads to a dismal outcome with a notable increased incidence of NRM. This result strongly supports the idea that Tregs play important roles after allo-HSCT in humans, as demonstrated in mouse models.
21-26
Our results indicating that pretransplantation Mog had such a huge impact on the clinical outcome after allo-HSCT are intriguing. The half-life of Mog is approximately 16 to 18 days, and the standard dose of Mog is 1 mg/kg once per week. 8 In a phase I trial of Mog, an much lower dose of 0.01 mg/kg showed a clinical response and led to lymphopenia, which suggests that this dose could exert clinically meaningful effects on normal lymphocytes and ATL cells. 8 Although no clear evidence exists about the threshold concentration of Mog to deplete Tregs, we can calculate that the concentration of Mog after 3 to 4 months following the administration of 1.0 mg/kg is still much higher than the concentration of Mog after 1 month postadministration of 0.01 mg/kg. As described previously, this concentration of Mog is considered to be sufficiently high to deplete Tregs in vivo. 8 Analyses of Tregs after administration of Mog have revealed that Mog significantly depletes Tregs in vivo. [27] [28] [29] [30] In two of these four studies, the frequency of Tregs in peripheral blood was serially monitored, and it was shown that it took half a year or longer for Tregs to recover after the administration of Mog.
27,29 However, the reports that assessed the impact of Mog on Tregs are still limited, which should be elucidated in future studies. The current results that a shorter interval between administration of Mog and allo-HSCT is associated with a worse clinical outcome implies the importance of Mog concentration upon allo-HSCT. Reports showed that the majority of Tregs in the early period after transplantation show a CD45RA 2 effector/memory phenotype. 30, 31 Because the effector/ memory-phenotype Treg exhibits CCR4, the use of Mog might result in the critical decrease of the overall Treg population. Therefore, the current results suggest the relevance of Tregs highly expressing CCR4 to establish immune tolerance after allo-HSCT. The possible mechanism why the interval between Mog and allo-HSCT is important should be clarified. When Mog is administered before allo-HSCT, it depletes host-derived Tregs at first. When allo-HSCT is conducted soon after Mog is administered, the concentration of Mog is high enough to deplete donor-derived Tregs as well, which increases the risk of acute GVHD. However, when a long interval exists between administration of Mog and allo-HSCT, the concentration of Mog decreases. Residual Mog then Abbreviations: ATLL, adult T-cell leukemia/lymphoma; BM, bone marrow; CR, complete remission; HR, hazard ratio; HSCT, hematopoietic stem-cell transplantation; Mog, mogamulizumab; PBSC, peripheral blood stem cells; PD, progressive disease; PR, partial remission; SD, stable disease.
might not deplete all donor-derived Tregs. In terms of the importance of recipient Tregs in the setting of allo-HSCT, not much data are available except for reports in mouse models. [21] [22] [23] [24] [25] [26] The importance of CCR4-expressing Tregs in allo-HSCT should be further elucidated both in animal models and in humans.
The results provoke the discussion of how Mog can be incorporated in patients with ATLL who are eligible for allo-HSCT. As shown in Figure 1D , patients with CR or PR had a favorable clinical outcome when the dismal outcome of patients with ATLL without allo-HSCT is considered, which suggests the presence of graft-versus-ATLL effects. 6, 19 Therefore, given that the risk of severe/corticosteroid-refractory GVHD could possibly increase with the use of pretransplantation Mog, we should not use Mog in such patients as further tumor reduction before allo-HSCT. In contrast, patients with SD or PD had a poorer clinical outcome after allo-HSCT, although some patients still achieved long-term survival. Such patients with chemorefractory ATLL could be candidates for the addition of Mog. However, we have to consider the interval between Mog and allo-HSCT because a shorter interval between Mog and allo-HSCT could lead to a significantly increased risk of NRM. Although we used 50 days as a cutoff value, the data do not assure that administration of Mog with a longer interval is safe because NRM rates tended to be higher in patients with a longer interval between Mog and allo-HSCT compared with those who did not receive Mog, albeit without the statistical significance. As aforementioned, Mog is expected to persist for . 50 days in vivo. In future trials, monitoring of Mog level and immune monitoring of Tregs in peripheral blood are warranted. In addition, adjustment of intensity in GVHD prophylaxis is necessary, although there is no consensus about how we can prevent www.jco.org severe GVHD in patients who received Mog before allo-HSCT. In consideration of corticosteroid refractoriness in patients who received Mog, use of in vivo T-cell depletion like antithymocyte globulin, which can decrease the ratio of effector T cells to Tregs because effector T cells are more efficiently depleted than Tregs, can contribute to the reduction of severe GVHD, 32, 33 or adoptive Treg therapy after the disappearance of Mog in the body can be applied to supplement insufficient Tregs, although this is not available in general clinical practice. [34] [35] [36] Although Mog was first approved only for ATLL, it has since been approved for other T-cell lymphomas in Japan. In the future, Mog could possibly be approved in the United States and other countries. Therefore, more transplantation-eligible patients could receive Mog in the future. All hematologists should take the risks and benefits of Mog into consideration before they use Mog in transplantation-eligible patients.
This study had some limitations. The heterogeneity of patient characteristics and the timing and dose of Mog can affect the clinical outcome. Patients in the Mog group had adverse patient characteristics, such as older age, more acute-type ATLL, and more likely to receive stem cells from an unrelated or mismatched related donor. Because of the retrospective nature of this study, it was not able to fully exclude uncontrolled confounding variables, even if we conducted multivariable analyses for each clinical outcome. These factors might have exaggerated the adverse impact of Mog on the clinical outcomes. The method of survey could also have had selection bias, although our current database of 996 patients, which was the largest in Japan, covered approximately two thirds of all allo-HSCT cases for ATLL. In addition, we do not have data on the immune reconstitution of T cells, including Tregs, after allo-HSCT and the concentration of residual Mog after allo-HSCT. The incorporation of such detailed laboratory data to further confirm the impact of Mog on the immune reconstitution is warranted. In addition, we did not have data on the onset of GVHD and GVHD prophylaxis, which might also affect the results in the analysis of GVHD.
In conclusion, this study suggests that the use of Mog before allo-HSCT significantly worsens clinical outcome mainly because of an increased risk of severe/corticosteroid-refractory acute GVHD. The results strongly support the clinical relevance of Tregs after allo-HSCT in humans, which is consistent with that in animal models. At present, it seems reasonable to pay careful attention to the use of Mog for patients with ATLL or other diseases who are eligible for allo-HSCT. The clinical safety and efficacy to intensify GVHD prophylaxis should be explored in patients who receive Mog before allo-HSCT.
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